Voxelotor Tablets Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 500 mg

Reference Brands: Oxbryta(US)

Category: Blood Disorder

Voxelotor inhibits hemoglobin S polymerization by binding to hemoglobin, increasing its oxygen affinity. This reduces sickling of red blood cells, decreasing hemolysis and improving anemia. Benefits include raising hemoglobin levels, reducing sickle cell crises, and enhancing quality of life for patients with sickle cell disease. Voxelotor tablets is available in Tablet and strengths such as 500 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Voxelotor tablets is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Voxelotor tablets can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Voxelotor, marketed as Oxbryta, is approved in the US by the FDA for treating sickle cell disease. In the EU, regulatory approval is pending or under review. Approval requires a comprehensive dossier including clinical trial data, safety, efficacy, pharmacovigilance, and manufacturing details. In the US, submission involves detailed clinical study review, while the EU follows EMA guidelines for authorization. For guidance on dossier preparation, regulatory pathways, and successful market entry strategies, visit PharmaTradz. Ensuring compliance with regional regulations is essential for the safe, approved, and effective use of voxelotor worldwide, supporting patients with sickle cell disease.